LigaChem Biosciences (LCB) is a public, clinical-stage biotechnology company headquartered in Daejeon, South Korea, with a U.S. office for in Boston, Massachusetts. LCB pioneers next-generation antibody–drug conjugates (ADCs) using its proprietary ConjuAll™ site-specific conjugation platform and LBG tumor-selective linker technology, enabling homogeneous, stable ADCs with optimized DAR and preferential payload release in tumors.

LCB has strong expertise in medicinal chemistry and is developing novel cytotoxic payloads as well as a pipeline of small molecule oncology therapeutics, further diversifying its innovation portfolio.